Clinical Trial Update: A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis [Phase 1]

View source ↗

Summary

A two-part, Phase 1, single-dose study of an IL-31 monoclonal antibody was conducted in healthy subjects and adults with atopic dermatitis; the trial status rep…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• IL-31 monoclonal antibody (anti-interleukin 31 monoclonal antibody)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Healthy Subjects and Atopic Dermatitis Subjects | Phase 1 | Status: COMPLETED